Preliminary positive results seen for microbiome-based C. diff treatment

A new microbiome-based treatment for Clostridioides difficile infection showed success in reducing recurrence of the infection at 8 weeks, according to preliminary results released by the manufacturer.“With RBX2660 and other microbiome restoration therapies, the things that are most exciting about these therapies is that we will finally be able to offer a standardized product and therapy to our patients,” Sahil Khanna, MBBS, of Mayo Clinic, told Healio Gastroenterology and Liver Disease. “RBX2660 is distinct from other therapies in several ways. One, it’s standardized.Read More

Share on facebook
Share on twitter
Share on linkedin